TOPICAL BEVACIZUMAB EYEDROPS FOR CORNEAL
NEOVASCULARISATIONPRELIMINARY RESULTS
Siveková D., Netuková M., Liehneová K., Vokrojová M., Kuchynka P., Studený P.
Department of Ophthalmology, 3rd Medical Faculty, Charles University, Prague, Czech Republic
The authors have no financial interest in the presentation material
PurposeTo present preliminary results of using topicalBevacizumab in patients with cornealneovascularisation.
Materials and methods Prospective study – under termis and conditions of ethical
committee of 3rd Medical faculty, Charles University, Prague. All patients were fully informed and signed a consent form
14 eyes of 13 consecutive adult patients (4 men, 9 women)
Mean age 59 years (42 – 81) Follow up time 3 months
Indications in our study Pterygium 3x Leucoma corneae 4x Risk keratoplasty 4x Neovascularisation after keratitis 1x St.p. acid burn 1x
Aplication and clinical evaluation
Bevacizumab eye drops (2,5mg/ml) – OFF LABEL USE 2 times daily for 14 days
Complete ophthalmic examination including BCVA, IOP, biomicroscopy, fundus – before and after 1, 2 and 3 month
Digital photographs of the cornea Corneal pattern for grading
96 identical triangels (72 peripheral, 24 central)
Evaluation was made by 1 doctor
Aplication
Clinical evaluation
ResultsCentral segments Peripheral segments
1 2 3 4 5 6 7 8 9 10 11 12 13 140
2
4
6
8
10
12
14
16
18
20
Month 3 Month 1 Before1 2 3 4 5 6 7 8 9 10 11 12 13 14
0
10
20
30
40
50
60
70
80
Month 3 Month 1 Before
Before Month 1 Month 3Peripheral segments 28,77 24,69 23,6
Central segments 4,385 3,77 3,62
Statistically significant change 1 and 3 months after treatment in peripheral segments (p=0,003)No statistically significant change 1 and 3 months after treatment in central segments (p>0,05)
ResultsBCVA
1 2 3 4 5 6 7 8 9 10 11 12 13 140.0
0.2
0.4
0.6
0.8
1.0
1.2
Before Month 3
Before
Month 3
Month 1
Before
Month 1
Month 3
Before
Month 1
Month 3
Conclusion The short term use of Bevacizumab eye drops
seems to be very effective treatment of corneal neovascularisation
We did not note any serious complication during the therapy. In two patients we observed temporarily some small epithelial defects.
Further prospective controlled studies with larger number of patients and long term results are required.
